Alnylam Pharmaceuticals Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Valuation Ratios
P/S Ratio13.5013.1428.1824.0230.64
P/B Ratio452.40-108.87-184.7934.4814.86
Price/Tangible Book452.4034.4814.86
Price/FCF572.67
Price/OCF230.62
Enterprise Value Ratios
EV/Revenue13.4813.2828.5023.5429.70
EV/FCF578.81
Profitability & Returns
Return on Equity (ROE)-5.26%-1.06%-0.70%
Return on Assets (ROA)-0.03%-0.05%-0.14%-0.13%-0.18%
Return on Capital Employed (ROCE)-0.06%-0.10%-0.28%-0.24%-0.29%
Leverage & Solvency Ratios
Debt/Equity40.89-12.16-16.513.721.57
Debt/FCF63.96
Liquidity Ratios
Current Ratio2.783.083.514.044.47
Quick Ratio2.612.863.173.794.23
Efficiency Ratios
Asset Turnover0.560.500.290.240.17
Inventory Turnover3.862.851.571.741.19
Yield & Distribution Ratios
Earnings Yield-0.01%-0.02%-0.04%-0.04%-0.06%
FCF Yield0.00%0.00%-0.02%-0.04%-0.05%
Buyback Yield-0.02%-0.03%-0.03%-0.03%-0.05%